Literature DB >> 20193849

Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.

Caroline C Bernardi1, Enilze de S F Ribeiro, Iglenir J Cavalli, Eleidi A Chautard-Freire-Maia, Ricardo L R Souza.   

Abstract

Increasing evidence supports the involvement of acetylcholinesterase and butyrylcholinesterase in cell proliferation control and differentiation, reinforcing the hypothesis that these enzymes might have an influence in tumorigenesis. It has already been shown that the cholinesterase genes are structurally altered or aberrantly expressed in a variety of tumor types. In this study, amplifications and deletions in the ACHE and BCHE genes were investigated in sporadic breast tumors using real-time polymerase chain reaction and the relative quantification method. The majority of the tumor tissues showed a notable number of both deletions and amplifications: 65.7% and 22.9%, respectively, in BCHE and 45.7% and 31.4%, respectively, in ACHE. Deletion of the ACHE gene was significantly correlated with amplification of the protooncogene ERBB2. Tumor size was significantly higher when the ACHE gene was amplified, and the total number of alterations (amplifications plus deletions) of the BCHE gene was positively correlated with tumor malignancy grade.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193849     DOI: 10.1016/j.cancergencyto.2009.10.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs.

Authors:  Stuart Creton; Marilyn J Aardema; Paul L Carmichael; James S Harvey; Francis L Martin; Robert F Newbold; Michael R O'Donovan; Kamala Pant; Albrecht Poth; Ayako Sakai; Kiyoshi Sasaki; Andrew D Scott; Leonard M Schechtman; Rhine R Shen; Noriho Tanaka; Hemad Yasaei
Journal:  Mutagenesis       Date:  2011-08-17       Impact factor: 3.000

2.  Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma.

Authors:  Ana Cristina Castillo-González; Susana Nieto-Cerón; Juan Pablo Pelegrín-Hernández; María Fernanda Montenegro; José Antonio Noguera; María Fuensanta López-Moreno; José Neptuno Rodríguez-López; Cecilio J Vidal; Diego Hellín-Meseguer; Juan Cabezas-Herrera
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

Review 3.  Role of acetylcholinesterase in lung cancer.

Authors:  Hui-Jun Xi; Ren-Pei Wu; Jing-Jing Liu; Ling-Juan Zhang; Zhao-Shen Li
Journal:  Thorac Cancer       Date:  2015-03-20       Impact factor: 3.500

4.  Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome.

Authors:  Peng Guo; Tianjie Pu; Shinan Chen; Yan Qiu; Xiaorong Zhong; Hong Zheng; Lina Chen; Hong Bu; Feng Ye
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

5.  Identification of molecular markers associated with the progression and prognosis of endometrial cancer: a bioinformatic study.

Authors:  JinHui Liu; Mingming Feng; SiYue Li; Sipei Nie; Hui Wang; Shan Wu; Jiangnan Qiu; Jie Zhang; WenJun Cheng
Journal:  Cancer Cell Int       Date:  2020-02-19       Impact factor: 5.722

6.  Exposure to ionizing radiation induced persistent gene expression changes in mouse mammary gland.

Authors:  Kamal Datta; Daniel R Hyduke; Shubhankar Suman; Bo-Hyun Moon; Michael D Johnson; Albert J Fornace
Journal:  Radiat Oncol       Date:  2012-12-05       Impact factor: 3.481

7.  Development of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines.

Authors:  M Ender Avci; Ayse Gokce Keskus; Seniye Targen; M Efe Isilak; Mehmet Ozturk; Rengul Cetin Atalay; Michelle M Adams; Ozlen Konu
Journal:  Sci Rep       Date:  2018-01-25       Impact factor: 4.379

8.  Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.

Authors:  Christian Gentzsch; Matthias Hoffmann; Yasuhiro Ohshima; Naoko Nose; Xinyu Chen; Takahiro Higuchi; Michael Decker
Journal:  ChemMedChem       Date:  2021-03-01       Impact factor: 3.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.